Here’s the introduction to their recently published piece

Cannabis Lobbying Spend Continues to Decrease

After reaching new highs in 2019, lobbying by cannabis companies and groups continues to fall in 2020.

By Nushin Rashidian
Federal lobbying spending by cannabis-focused entities has continued to decline in 2020, according to a Cannabis Wire analysis of the latest lobbying disclosures. This is a continuation of a downward trend that began in early 2020, following an unprecedented rise in lobbying spending by these entities in 2019.

Last year, cannabis advocates saw historic victories and momentum at the national level. The MORE Act, which the House Judiciary Committee passed in November, was the first legalization bill to get a Congressional vote. The SAFE Banking Act, which the House passed in September, was the first-ever standalone cannabis legislation to receive a House vote.

But then, nothing. The bills stalled and the coronavirus pandemic hit, spurring cutbacks and layoffs across an already reeling industry. While there have been efforts to include language similar to the SAFE Banking Act in federal coronavirus legislation, those, too, have hit a wall.

A Cannabis Wire analysis of lobbying disclosures by cannabis-focused companies or groups for the second quarter of 2020 shows, as of the July 20 deadline, a total spend of approximately $1.38 million. This is a decline from an approximate total of $1.67 million in Q1, and a little over $2 million in Q4 2019.

Read the full article :